EuroMed Therapeutics is building the ninth Israeli
Post# of 85498
(Total Views: 597)
Posted On: 08/14/2019 5:59:53 PM
EuroMed Therapeutics is building the ninth Israeli licensed producer to capitalize on the domestic medical marijuana market and Europe’s nascent export market — worth upwards of $66 billion.
Israeli Licensed Producer: EuroMed is building Israel’s ninth licensed producer, compared to more than 160 LPs across Canada.
Low Cost Production: Israel has an ideal climate for year round outdoor cannabis production — significantly lowering costs.
European End Markets: Israel’s strategic location makes it ideal for exporting to Europe, where consumers pay $18+ per gram.
Access to Talent: Israel is a global leader in cannabis research, as well as a biotech and pharmaceutical hub.
Israeli Licensed Producer: EuroMed is building Israel’s ninth licensed producer, compared to more than 160 LPs across Canada.
Low Cost Production: Israel has an ideal climate for year round outdoor cannabis production — significantly lowering costs.
European End Markets: Israel’s strategic location makes it ideal for exporting to Europe, where consumers pay $18+ per gram.
Access to Talent: Israel is a global leader in cannabis research, as well as a biotech and pharmaceutical hub.
(6)
(0)Univec Conglomerate Inc (UNVC) Stock Research Links
Scroll down for more posts ▼